A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Hackensack Meridian Health
Novartis
University College, London
Hackensack Meridian Health
Hackensack Meridian Health
National Cancer Institute (NCI)
Geneve TEAM Ambulances
National Cancer Institute (NCI)
University of Nebraska
Washington University School of Medicine
Stanford University
BeOne Medicines
AIDS Malignancy Consortium
City of Hope Medical Center
University of Massachusetts, Amherst
Thomas Jefferson University
Gilead Sciences
Dana-Farber Cancer Institute
Pharmacyclics LLC.
SWOG Cancer Research Network
University of Chicago
University of Miami
Hoffmann-La Roche
Takeda
Gamida Cell ltd
National Institutes of Health Clinical Center (CC)
BeOne Medicines
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BeOne Medicines
Seagen Inc.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Mayo Clinic
Eli Lilly and Company
Espad Pharmed
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Iowa
Children's Hospital of Philadelphia
M.D. Anderson Cancer Center
Hope Biosciences Research Foundation
Brown University
Aileron Therapeutics, Inc.
M.D. Anderson Cancer Center
Acerta Pharma BV
Pfizer